Quantumzyme Corp. (OTC: QTZM) announced the publication of its latest research in the Journal of Molecular Graphics & Modelling, highlighting a fully computational enzyme engineering approach for sustainable pharmaceutical manufacturing. The peer-reviewed study, titled in the journal, explores the use of virtual screening and computational modeling to evaluate transaminase enzyme variants before laboratory testing, specifically for the asymmetric synthesis of L-HPE—a chiral intermediate relevant to certain ACE inhibitor drugs.
Rather than relying solely on traditional experimental iteration, the research employed large-scale virtual screening and ranking methodologies to assess enzyme–substrate interactions, catalytic alignment, and structural stability under defined simulation conditions. This approach allowed the identification of enzyme candidates for subsequent experimental consideration, potentially improving research efficiency and reducing the need for costly laboratory trials.
“Publishing this research in the Journal of Molecular Graphics & Modelling represents an important scientific milestone for Quantumzyme,” said Naveen Kulkarni, Chief Executive Officer. “This study contributes to the growing body of evidence supporting computational enzyme engineering as a complementary tool in biocatalyst development. At Quantumzyme, we are focused on integrating computational modeling with experimental workflows. By evaluating enzyme variants virtually prior to laboratory testing, we aim to improve research efficiency and better inform downstream validation efforts.”
The publication underscores the expanding role of computational modeling in biocatalysis research. By supporting early-stage evaluation and hypothesis testing, in silico methodologies may help reduce experimental iteration and improve the prioritization of enzyme candidates for laboratory study. The full paper is available at https://www.sciencedirect.com/science/article/pii/S1093326326000343.
The company emphasized that the publication does not represent regulatory approval, commercial validation, or confirmation of manufacturing readiness. Additional experimental testing, optimization, and scale-up would be required before any potential industrial application.
In a separate update, Quantumzyme announced that FINRA has received all necessary information to complete its review of the company’s previously announced corporate name change and corresponding trading symbol request. Based on current communications, the company anticipates that, subject to FINRA’s final approval, the name change and new trading symbol are expected in the coming days. Regulatory processes remain outside of the company’s control, and no assurance can be given regarding the exact timing or approval of the request. Upon effectiveness, Quantumzyme intends to issue a separate announcement confirming the official name and ticker symbol change.
For more information, visit www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
